无法切除胰腺癌患者端粒酶肽疫苗接种:剂量升级I / II期研究。

文章的细节

引用

复制到剪贴板

伯恩哈特SL, Gjertsen可Trachsel年代,穆勒M,埃里克森是的,giove - M, Buanes T, Gaudernack G

无法切除胰腺癌患者端粒酶肽疫苗接种:剂量升级I / II期研究。

Br J癌症。2006年12月4日,95 (11):1474 - 82。Epub 2006年10月24日。

PubMed ID

17060934 (在PubMed

]

文摘

不实用的胰腺癌患者预后的平均寿命为3 - 6个月。新的治疗方法是急需的。端粒酶表达在85 - 90%的胰腺癌,和免疫原性端粒酶肽为特征的。I / II期研究探讨安全、耐受性和immunogenecity端粒酶肽疫苗接种。生存的病人也被记录下来。48切除胰腺癌患者接受了皮内注射的端粒酶肽GV1001三个剂量水平,结合集落刺激因子。治疗期是10周。每月助推器疫苗作为后续治疗。免疫反应测定dth皮肤反应和体外t细胞增殖。GV1001耐受性良好。 Immune responses were observed in 24 of 38 evaluable patients, with the highest ratio (75%) in the intermediate dose group. Twenty-seven evaluable patients completed the study. Median survival for the intermediate dose-group was 8.6 months, significantly longer for the low- (P = 0.006) and high-dose groups (P = 0.05). One-year survival for the evaluable patients in the intermediate dose group was 25%. The results demonstrate that GV1001 is immunogenic and safe to use. The survival data indicate that induction of an immune response is correlated with prolonged survival, and the vaccine may offer a new treatment option for pancreatic cancer patients, encouraging further clinical studies.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Tertomotide